Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

(R)-SLV 319

Cat. No.: HY-121616

(R)-SLV 319 is a potent and selective **cannabinoid receptor 1 (CB1)** antagonist with a K_i value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Zevaquenabant

((Rac)-MRI-1867)

Cat. No.: HY-141411

(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a **cannabinoid receptor type 1 (CB_1R)/iNOS** antagonist, with a K_i of 5.7 nM for CB_1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(±)-Ibipinabant

((±)-SLV319; (±)-BMS-646256)

Cat. No.: HY-14791A

(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (**CB-1**) receptor antagonist with an IC_{50} of 22 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

2-Arachidonoylglycerol

Cat. No.: HY-W011051

2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg (26.4 mM * 100 μL in Acetonitrile),

2-Arachidonoylglycerol-d5

Cat. No.: HY-W011051S1

2-Arachidonoylglycerol-d5 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Arachidonoylglycerol-d8

Cat. No.: HY-W011051S

2-Arachidonoylglycerol-d8 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Palmitoylglycerol

(2-Palm-Gl)

Cat. No.: HY-W013788

2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest **cannabinoid receptor CB1** agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-836339

Cat. No.: HY-12761

A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

AM-6538

Cat. No.: HY-120423

AM6538 is a long-acting, high affinity and pseudo-irreversible **cannabinoid (CB)** antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AM251

Cat. No.: HY-15443

AM251 is a selective **cannabinoid 1** (**CB1**) receptor antagonist with an IC_{50} of 8 nM. AM251 also acts as a potent **GPR55** agonist with an EC_{50} of 39 nM.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AM281

Cat. No.: HY-13505

AM281 is a selective **CB1 receptor** antagonist with an IC_{50} of 9.91 nM. AM281 inhibits CB2 receptor with an IC_{50} of 13000 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM6545

Cat. No.: HY-110206

AM6545 is a peripherally active, **cannabinoid receptor** antagonist with limited brain penetration. AM6545 binds to **CB1** and **CB2** receptors with K_is of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM9405

Cat. No.: HY-112707

AM9405 is a novel peripherally active **cannabinoid type 1 (CB1)** and **serotonin type 3 receptor** agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC_{50}s of 45.71 and 0.076 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APICA

Cat. No.: HY-101375

APICA is a potent CB_1 and CB_2 **receptors** agonist with EC_{50} values of 118 nM and 37 nM against CB_1 and CB_2 receptors, respectively. APICA possess cannabimimetic activity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arvanil

(N-Vanillylarachidonamide)

Cat. No.: HY-103333

Arvanil is a ligand for **vanilloid receptor 1 (VR1)** and **cannabinoid 1 (CB1)**. Arvanil can inhibit spasticity, as a potent neuroprotectant.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Auriculasin

Cat. No.: HY-N2911

Auriculasin is a nature product isolated from **Limonium leptophyllum**. Auriculasin has activity toward **cannabinoid receptor type 1 (CB1)** with an IC_{50} value of 8.92 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD1940

Cat. No.: HY-119104

AZD1940 is an orally active, high affinity **cannabinoid CB1/CB2 receptor** agonist with **pK**$_i$ values of 7.93 and 9.06 for **human CB1R** and **CB2R**, respectively. AZD1940 shows a robust analgesia action.



Purity: 99.45%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BAY 38-7271

Cat. No.: HY-119744

BAY 38-7271 is selective and highly potent and cannabinoid **CB_1/CB_2 receptor** agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB_1 receptor and CB_2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bay 59-3074

Cat. No.: HY-100488

Bay 59-3074 is a selective cannabinoid **CB_1/CB_2 receptor** partial agonist with K_i values of 48.3 and 45.5 nM at human **CB_1** and **CB_2** receptors, respectively. Bay 59-3074 has analgesic properties.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BML-190

(Indomethacin morpholinylamide; IMMA)

Cat. No.: HY-15420

BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CB1 antagonist 1

Cat. No.: HY-U00397

CB1 antagonist 1 is an antagonist of **CB1 receptor**, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB1 antagonist 2

(AM4113)

Cat. No.: HY-116649

CB1 antagonist 2 is caimabinoid 1 (**CB1**) antagonist extracted from patent WO2016184310A1, compound 3, inhibits CB1 in vivo with an IC_{50} of 25.5 nM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CB1 inverse agonist 1

Cat. No.: HY-135280

CB1 inverse agonist 1 is a highly potent, orally active, and specific inverse agonist of **CB1 receptor** with IC_{50}s of 7.5 nM and 4100 nM for **CB1** and **CB2 receptors**, respectively. Anorexigenic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB1-IN-1

(BPRCB1184)

Cat. No.: HY-12790

CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CB2 modulator 1

Cat. No.: HY-135419

CB2 modulator 1 (compound 130) is a potent **CB2** modulator. CB2 modulator 1 has the potential for immunedisorders, inflammation, osteoporosis, renal ischemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2 receptor agonist 2

Cat. No.: HY-132217

CB2 receptor agonist 2 is a potent and selective agonist for the **CB2** (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for **CB2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2 receptor agonist 3

(GP2a)

Cat. No.: HY-107471

CB2 receptor agonist 3 is a robust and selective **CB2** cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2R PAM

Cat. No.: HY-131004

CB2R PAM is an orally active **cannabinoid type-2 receptors (CB2Rs)** positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2R-IN-1

Cat. No.: HY-100328

CB2R-IN-1 is a potent **cannabinoid CB_2** receptor inverse agonist with a K_i of 0.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB65

Cat. No.: HY-110047

CB65 is a potent and high affinity **CB2** selective agonist with a K_i value of 3.3 nM. CB65 exhibits a K_i of >1000 nM for CB1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Drinabant

(AVE1625)

Cat. No.: HY-14788

Drinabant (AVE1625) is an orally active **CB1 receptor** antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC_{50} values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EHP-101

(VCE-004.8)

Cat. No.: HY-128872

EHP-101 (VCE-004.8) is an orally active, specific **PPARγ** and CB_2 receptor dual agonist. EHP-101 inhibits **prolyl-hydroxylases (PHDs)** and activates the **HIF** pathway. EHP-101, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GAT211

Cat. No.: HY-113689

GAT211 is a **cannabinoid 1 receptor (CB1R)** positive allosteric modulator (PAM). GAT211 can be used for neuropathic and/or inflammatory pain research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GAT228

Cat. No.: HY-120953

GAT228, the enantiomer of GAT211, is an allosteric **cannabinoid receptor 1 (CB1)** ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GAT564

Cat. No.: HY-144705

GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (**CB1R**) with EC_{50}s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GP1a

Cat. No.: HY-110050

GP1a is a potent agonist of cannabinoid receptor 2 (**CB2**). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW-405833

(L768242)

Cat. No.: HY-110036

GW-405833 (L768242) is a potent, selective **cannabinoid receptor 2 (CB_2)** agonist with an EC_{50} of 50.7 nM. GW-405833 also behaves as a noncompetitive CB_1 antagonist. GW-405833 suppresses inflammatory and neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW842166X

Cat. No.: HY-14167

GW842166X is a potent and selective **cannabinoid receptor 2** (CB2) agonist with IC_{50} values of 63 and 91 nM for human and rat CB2, respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Hemopressin (human, mouse)

Cat. No.: HY-P1091

Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of **CB1** cannabinoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hemopressin(human, mouse) TFA

Cat. No.: HY-P1091A

Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of **CB1** cannabinoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hemopressin(rat)

Cat. No.: HY-P1090

Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of **CB1** cannabinoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hemopressin(rat) TFA

Cat. No.: HY-P1090A

Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of **CB1** cannabinoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibipinabant

(SLV319; BMS-646256)

Cat. No.: HY-14791

Ibipinabant (SLV319) is a potent, selective and orally active antagonist of **cannabinoid CB1 receptor**, with a K_i of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JD-5037

Cat. No.: HY-18697

JD-5037 is a potent **CB_1R** antagonist with an **IC_{50}** of 1.5 nM.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JTE-907

Cat. No.: HY-103325

JTE-907 is a highly selective, orally active **CB2 receptor** inverse agonist and exerts anti-inflammatory effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KM-233

Cat. No.: HY-123410

KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leelamine

Cat. No.: HY-W005629

Leelamine is a weak agonist of **cannabinoid receptors CB1** and **CB2**. Leelamine also inhibits **pyruvate dehydrogenase kinases (PDKs)**. Leelamine exhibits anti-tumor activity.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Leelamine hydrochloride

Cat. No.: HY-110028

Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees.



Purity: >98%
Clinical Data:
Size: 5 mg

Leelamine-d4 hydrochloride

Cat. No.: HY-110028S

Leelamine-d4 hydrochloride is the deuterium labeled Leelamine hydrochloride. Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LEI-101

Cat. No.: HY-124283A

LEI-101 is a potent, selective, and orally bioavailable **cannabinoid CB2 receptor** agonist, with a pEC_{50} of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

LY2828360

Cat. No.: HY-16642A

LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB_2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY320135

Cat. No.: HY-W011040

LY320135 is a potent and selective antagonist of **CB1** receptor, with a K_i of 141 nM. LY320135 also binds to **5-HT$_2$** and **muscarinic receptors** with K_is of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MDA 19

Cat. No.: HY-15451

MDA 19 is a potent and selective agonist of human **cannabinoid receptor 2 (CB2)**, with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MJ15

Cat. No.: HY-103327

MJ15 is a potent and selective **CB1 receptor** antagonist with a K_i of 27.2 pM and an **IC_{50}** of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Arachidonyldopamine

Cat. No.: HY-110018

N-Arachidonyldopamine is a potent and selective endogenous **CB1 receptor agonist with a K_i of 250 nM. N-Arachidonyldopamine is also a potent and selective TRPV1 agonist an with EC_{50} of ~ 50 nM.**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Oleoyl glycine

Cat. No.: HY-113204

N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of **CB1 receptor** and **Akt** signaling pathway in 3T3-L1 adipocyte.

Purity: ≥98.0%
Clinical Data:
Size: 10 mM × 1 mL, 10 mg

NESS 0327

Cat. No.: HY-117139

NESS 0327 is a **cannabinoid** antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NIDA-41020

Cat. No.: HY-103326

NIDA-41020 is a potent and selective **cannabinoid receptor 1(CB1)** antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Noladin ether

Cat. No.: HY-110014

Noladin ether is a potent and selective agonist of **cannabinoid CB_1 receptor**, with a K_i of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-2050

Cat. No.: HY-133533

O-2050 is a high affinity **cannabinoid CB_1 receptor** antagonist with a K_i of 2.5 nM. O-2050 inhibits cannabinoid CB_2 receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olivetol

Cat. No.: HY-W008364

Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors **CB1** and **CB2**. Olivetol also inhibits **CYP2C19** and **CYP2D6** activity, with IC_{50}s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Olorinab

(APD 371)

Cat. No.: HY-111110

Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 **(CB_2)** agonist, with an **EC_{50}** of 6.2 nM for hCB_2.



Purity: 98.86%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OMDM-6

Cat. No.: HY-135882

OMDM-6 is a hybrid agonist of **vanilloid receptor type 1 (VR1, TRPV1)** (EC_{50}=75 nM) and **cannabinoid receptor type 1 (CB1)** (K_i=3.2 μM). OMDM-6 inhibits **anandamide cellular uptake (ACU)** with a **K_i** of 7.0 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Org 27569

Cat. No.: HY-13288

Org 27569 is a potent **CB1 receptor** allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Otenabant

(CP-945598)

Cat. No.: HY-10871

Otenabant is a potent and selective **cannabinoid receptor CB1** antagonist with **K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.



Purity: 99.33%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Otenabant Hydrochloride

(CP 945598 Hydrochloride)

Cat. No.: HY-10871A

Otenabant Hydrochloride is a potent and selective **cannabinoid receptor CB1** antagonist with **K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Palmitoyl serinol

(N-Palmitoyl serinol)

Cat. No.: HY-125407

Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PGN36

Cat. No.: HY-146134

PGN36 (Compound 18) is a selective **cannabinoid CB_2 receptor (CB_2R)** antagonist with a **K_i** of 0.09 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PM226

Cat. No.: HY-136238

PM226 is a selective **cannabinoid CB2R** agonist (**K_i (CB2R)**=13 nM; **EC_{50} (CB2R)**=39 nM; K_i (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pregnenolone

(3β-Hydroxy-5-pregnen-20-one)

Cat. No.: HY-B0151

Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: 98.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Pregnenolone monosulfate

(3β-Hydroxy-5-pregnen-20-one monosulfate) **Cat. No.:** HY-B1739

Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pregnenolone monosulfate sodium

(3β-Hydroxy-5-pregnen-20-one monosulfate sodium) **Cat. No.:** HY-110189

Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.



Purity: ≥95.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Pregnenolone monosulfate sodium-13C2,d2

(3β-Hydroxy-5-pregnen-20-one monosulfate sodium-13C2,d2) **Cat. No.:** HY-110189S

Pregnenolone monosulfate sodium-13C2,d2 is the 13C- and deuterium labeled Pregnenolone monosulfate sodium.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pregnenolone monosulfate-d4 sodium

(3β-Hydroxy-5-pregnen-20-one monosulfate-d4 sodium) **Cat. No.:** HY-110189S1

Pregnenolone monosulfate-d4 (sodium) is the deuterium labeled Pregnenolone monosulfate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pregnenolone-d4-1

(3β-Hydroxy-5-pregnen-20-one-d4-1) **Cat. No.:** HY-B0151S2

Pregnenolone-d4-1 (3β-Hydroxy-5-pregnen-20-one-d4-1) is the deuterium labeled Pregnenolone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSNCBAM-1

Cat. No.: HY-110179

PSNCBAM-1 is a selective **CB1 receptor** allosteric antagonist with an **EC_{50}** of 0.1 μM. PSNCBAM-1 can be used in the researches of obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rimonabant

(SR141716) **Cat. No.:** HY-14136

Rimonabant (SR141716) is a highly potent, brain penetrated and selective central **cannabinoid receptor (CB1)** antagonist with a **K_i** of 1.8 nM. Rimonabant (SR141716) also inhibits **Mycobacterial membrane protein Large 3 (MMPL3)**.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Rimonabant Hydrochloride

(SR 141716A Hydrochloride) **Cat. No.:** HY-14137

Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central **cannabinoid receptor (CB1)** antagonist with an **K_i** of 1.8 nM.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Rimonabant-d10

(SR141716-d10) **Cat. No.:** HY-14136S

Rimonabant-d10 is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rimonabant-d10 hydrochloride

Cat. No.: HY-14137S

Rimonabant-d10 (SR 141716A-d10) hydrochloride is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central **cannabinoid receptor (CB1)** antagonist with an **K_i** of 1.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

RTICBM-189

Cat. No.: HY-145196

RTICBM-189 is a potent, brain-penetrant allosteric modulator of the **cannabinoid type-1 (CB_1)** receptor with a **pIC_{50}** of 7.54 in Ca^{2+} mobilization assay. RTICBM-189 has pIC_{50}s of 5.29 and 6.25 for hCB_1 and mCB_1, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RVD-Hpα

Cat. No.: HY-P1397

RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a **CB1 cannabinoid receptor** agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2.

RVDPVNFKLLSH

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RVD-Hpα TFA

Cat. No.: HY-P1397A

RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective **CB1 receptor** agonist. RVD-Hpα TFA increases intracellular Ca^{2+} levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

RVDPVNFKLLSH

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

S-777469

Cat. No.: HY-145153

S-777469 is a selective and orally available cannabinoid type 2 receptor **(CB2)** agonist with a **K_i** of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH 336

(SCH-225336)

Cat. No.: HY-121852

SCH 336 is a potent, selective, inverse and orally active **CB2** agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR144528

Cat. No.: HY-13439

SR144528 is a potent and selective **CB2 receptor** antagonist with a **K_i** of 0.6 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taranabant

(MK-0364)

Cat. No.: HY-10013

Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding **K_i** of 0.13 nM for the human CB1R in vitro.



Purity: 99.03%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Taranabant ((1R,2R)stereoisomer)

(MK0364 (1R,2R)stereoisomer)

Cat. No.: HY-10013B

Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective **cannabinoid 1** (**CB1**) receptor inverse agonist.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Taranabant racemate

(MK-0364 racemate)

Cat. No.: HY-10013A

Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the **Cannabinoid-1** (**CB1**) **receptor** extracted from patent WO 2004048317 A1.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tedalinab

(GRC-10693)

Cat. No.: HY-14900

Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 **(CB2)** agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrahydromagnolol

(Magnolignan)

Cat. No.: HY-116637

Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective **cannabinoid CB2 receptor** agonist with an EC_{50} of 170 nM and a K_i of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for **CB2 receptor** than CB1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

TM38837

Cat. No.: HY-112340

TM38837 is a peripheral selective **cannabinoid receptor type 1 (CB1)** receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UCM707

Cat. No.: HY-103341

UCM707, a potent and selective inhibitor of **endocannabinoid uptake**, potentiates hypokinetic and antinociceptive effects of Anandamide.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vicasinabin

Cat. No.: HY-145604

Vicasinabin is the potent agonist of **cannabinoid receptor 2** (**CB2**). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Voacamine

Cat. No.: HY-N6932

Voacamine, an indole alkaloid, exhibits potent **cannabinoid CB1 receptor** antagonistic activity. Voacamine also inhibits **P-glycoprotein** (**P-gp**) action in multidrug-resistant tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

WIN 55,212-2 Mesylate

((R)-(+)-WIN 55212)

Cat. No.: HY-13291

WIN 55,212-2 Mesylate is a potent aminoalkylindole **cannabinoid (CB) receptor** agonist with K_is of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Yangonin

Cat. No.: HY-N0919

Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an IC_{50} and a K_i of 1.79 μM and 0.72 μM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ZCZ011

Cat. No.: HY-118140

ZCZ011 is a potent and brain penetrant **cannabinoid 1 (CB1) receptor** positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zevaquenabant

((S)-MRI-1867)

Cat. No.: HY-141411A

Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid **CB1 receptor** and inducible NOS **(iNOS)** antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Caryophyllene

((-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene)

Cat. No.: HY-N1415

β-Caryophyllene is a **CB2 receptor** agonist.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 500 mg

β-Caryophyllene-d2

Cat. No.: HY-N1415S

β-Caryophyllene-d2 is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg